Investors, CBD Pharma Co. Reach Deal Over Clinical Trial Suit
Law360 (May 7, 2021, 9:19 PM EDT) -- Stockholders pressing consolidated, derivative damage claims against CBD drugmaker Zynerba Pharmaceuticals sought preliminary approval Friday for settlement of a federal suit in Delaware targeting damage to the company from undisclosed adverse effects during a drug trial, in a deal that includes a minimum five-year battery of corporate governance reforms.
The motion in the U.S. District Court for the District of Delaware followed docketing of a proposed $4 million class award in a Pennsylvania federal court for direct damages to stockholders arising from the same adverse episode.
Litigation in Delaware focused on harm to the company from alleged breaches of fiduciary duty, unjust...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!